TipRanks

Notifications

Wedbush Keeps a Buy Rating on Clearside Biomedical (CLSD)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Clearside Biomedical (CLSDResearch Report), with a price target of $19.00. The company’s shares closed last Monday at $5.69.

According to TipRanks.com, Moussatos is a 2-star analyst with an average return of 1.4% and a 35.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.

Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $13.33, representing a 136.3% upside. In a report issued on October 13, JMP Securities also reiterated a Buy rating on the stock with a $10.00 price target.

See the top stocks recommended by analysts >>

Clearside Biomedical’s market cap is currently $339.6M and has a P/E ratio of -13.00. The company has a Price to Book ratio of 17.56.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Read More on CLSD:

Tags: